Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer von SONDEL, P. M, KOHLER, P. C, HANK, J. A, MOORE, K. H, ROSENTHAL, N. S, SOSMAN, J. A, BECHHOFER, R, STORER, B

Volltext

New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma von Flaherty, Keith T., Sosman, Jeff A., Atkins, Michael B.

Volltext

New options and new questions: how to select and sequence therapies for patients with metastatic melanoma von Flaherty, Keith T, Sosman, Jeff A, Atkins, Michael B

Volltext

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity von SOSMAN, J. A, KOHLER, P. C, HANK, J, MOORE, K. H, BECHHOFER, R, STORER, B, SONDEL, P. M

Volltext

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin von Sosman, Jeff A., Kohler, Peter C., Hank, Jacquelyn A., Moore, Karen H., Bechhofer, Robin, Storer, Barry, Sonde, Paul M.

Volltext

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation von VOSS, S. D, HANK, J. A, NOBIS, C. A, FISCH, P, SOSMAN, J. A, SONDEL, P. M

Volltext

The cellular immunotherapy of cancer: Current and potential uses of interleukin-2 von Sondel, Paul M., Hank, Jacquelyn A., Kohler, Peter C., Sosman, Jeff A., Weil-Hillman, Gilda, Fisch, Paul, Bach, Fritz H.

Volltext

Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom von Sosman, Jeff A., Hank, Jacquelyn A., Moore, Karen H., Borchert, Agnes, Schell, Kathleen, Kohler, Peter C., Goldstein, David, Bechhofer, Robin, Storer, Barry, Albertini, Mark R., Leung, Pearl E., Levitt, Daniel, Sondel, Paul M.

Volltext

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1 von Sosman, Jeff A., Kohler, Peter C., Hank, Jacquelyn, Moore, Karen H., Bechhofer, Robin, Storer, Barry, Sondel, Paul M.

Volltext

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors von Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff

Volltext

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment von Vilgelm, Anna E, Johnson, C Andrew, Prasad, Nripesh, Yang, Jinming, Chen, Sheau-Chiann, Ayers, Gregory D, Pawlikowski, Jeff S, Raman, Dayanidhi, Sosman, Jeffrey A, Kelley, Mark, Ecsedy, Jeffrey A, Shyr, Yu, Levy, Shawn E, Richmond, Ann

Volltext

MEK + CDK4 a regimen for non-BRAF V6000 melanoma von Sosman, Jeff

Volltext

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma von KIRKWOOD, John M, BASTHOLT, Lars, DUMMER, Reinhard, ROBERT, Caroline, SOSMAN, Jeff, LARKIN, James, HERSEY, Peter, MIDDLETON, Mark, CANTARINI, Mireille, ZAZULINA, Victoria, KEMSLEY, Karin

Volltext

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells von Vilgelm, Anna E, Pawlikowski, Jeff S, Liu, Yan, Hawkins, Oriana E, Davis, Tyler A, Smith, Jessica, Weller, Kevin P, Horton, Linda W, McClain, Colt M, Ayers, Gregory D, Turner, David C, Essaka, David C, Stewart, Clinton F, Sosman, Jeffrey A, Kelley, Mark C, Ecsedy, Jeffrey A, Johnston, Jeffrey N, Richmond, Ann

Volltext

The state of melanoma: challenges and opportunities von Merlino, Glenn, Herlyn, Meenhard, Fisher, David E., Bastian, Boris C., Flaherty, Keith T., Davies, Michael A., Wargo, Jennifer A., Curiel-Lewandrowski, Clara, Weber, Michael J., Leachman, Sancy A., Soengas, Maria S., McMahon, Martin, Harbour, J. William, Swetter, Susan M., Aplin, Andrew E., Atkins, Michael B., Bosenberg, Marcus W., Dummer, Reinhard, Gershenwald, Jeffrey E., Halpern, Allan C., Herlyn, Dorothee, Karakousis, Giorgos C., Kirkwood, John M., Krauthammer, Michael, Lo, Roger S., Long, Georgina V., McArthur, Grant, Ribas, Antoni, Schuchter, Lynn, Sosman, Jeffrey A., Smalley, Keiran S., Steeg, Patricia, Thomas, Nancy E., Tsao, Hensin, Tueting, Thomas, Weeraratna, Ashani, Xu, George, Lomax, Randy, Martin, Alison, Silverstein, Steve, Turnham, Tim, Ronai, Ze'ev A.

Volltext

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors von Puzanov, Igor, Lindsay, Colin R, Goff, Laura, Sosman, Jeff, Gilbert, Jill, Berlin, Jordan, Poondru, Srinivasu, Simantov, Ronit, Gedrich, Rich, Stephens, Andrew, Chan, Emily, Evans, T R Jeffry

Volltext

Aberrant DNA methylation in malignant melanoma von Schinke, Carolina, Mo, Yongkai, Yu, Yiting, Amiri, Kathy, Sosman, Jeff, Greally, John, Verma, Amit

Volltext

352. Characteristics Associated with Pre-Frailty in Older People Living with HIV von Mazonson, Peter, Loo, Theoren, Berko, Jeff, Chan, Sarah-Marie, Westergaard, Ryan, Sosman, James

Volltext

Abstract 853: Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients von Bordeaux, Jennifer, Johnson, Douglas, Sosman, Jeffrey, Kim, Ju Young, Vaupel, Christine, Dabbas, Bashar, Cates, Justin, Hall, Jeff, Lameh, Jelveh, Tangri, Shabnam, Dakappagari, Naveen

Volltext

Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors von Sullivan, Ryan J., Amaria, Rodabe N., Lawrence, Donald P., Brennan, John, Leister, Cathie, Singh, Rajendra, Legos, Jeff, Thurm, Holger, Yan, Li, Flaherty, Keith T., Davies, Michael A., Sosman, Jeffrey

Volltext